Announcement • Apr 24
Shandong Wit Dyne Health Co.,Ltd., Annual General Meeting, May 20, 2026 Shandong Wit Dyne Health Co.,Ltd., Annual General Meeting, May 20, 2026, at 14:30 China Standard Time. Location: The Company's Meeting Room, Jinan, Shandong China Reported Earnings • Apr 24
First quarter 2026 earnings released: EPS: CN¥0.47 (vs CN¥0.78 in 1Q 2025) First quarter 2026 results: EPS: CN¥0.47 (down from CN¥0.78 in 1Q 2025). Revenue: CN¥412.3m (down 33% from 1Q 2025). Net income: CN¥110.6m (down 39% from 1Q 2025). Profit margin: 27% (down from 30% in 1Q 2025). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 3% per year whereas the company’s share price has fallen by 8% per year. Announcement • Mar 31
Shandong Wit Dyne Health Co.,Ltd. to Report Q1, 2026 Results on Apr 24, 2026 Shandong Wit Dyne Health Co.,Ltd. announced that they will report Q1, 2026 results on Apr 24, 2026 Announcement • Dec 31
Shandong Wit Dyne Health Co.,Ltd. to Report Fiscal Year 2025 Results on Apr 24, 2026 Shandong Wit Dyne Health Co.,Ltd. announced that they will report fiscal year 2025 results on Apr 24, 2026 Reported Earnings • Oct 25
Third quarter 2025 earnings released: EPS: CN¥0.30 (vs CN¥0.14 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.30 (up from CN¥0.14 in 3Q 2024). Revenue: CN¥432.1m (up 93% from 3Q 2024). Net income: CN¥70.6m (up 110% from 3Q 2024). Profit margin: 16% (up from 15% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Announcement • Sep 30
Shandong Wit Dyne Health Co.,Ltd. to Report Q3, 2025 Results on Oct 25, 2025 Shandong Wit Dyne Health Co.,Ltd. announced that they will report Q3, 2025 results on Oct 25, 2025 Announcement • Aug 28
Shandong Wit Dyne Health Co.,Ltd. Approves Interim Cash Dividend for 2025 Shandong Wit Dyne Health Co.,Ltd. at 1st Extraordinary General Meeting of 2025 on 26 August 2025, during which the company approved 2025 interim profit distribution plan of
Cash dividend/10 shares (tax included): CNY 5.00000000. Reported Earnings • Aug 12
Second quarter 2025 earnings released: EPS: CN¥0.66 (vs CN¥0.70 in 2Q 2024) Second quarter 2025 results: EPS: CN¥0.66 (down from CN¥0.70 in 2Q 2024). Revenue: CN¥554.2m (down 4.9% from 2Q 2024). Net income: CN¥155.1m (down 5.0% from 2Q 2024). Profit margin: 28% (in line with 2Q 2024). Revenue is forecast to grow 9.1% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Announcement • Aug 09
Shandong Wit Dyne Health Co.,Ltd. Proposes Interim Cash Dividend for the Year 2025 Shandong Wit Dyne Health Co.,Ltd. at its EGM to be held on August 26, 2025 Proposed Interim Cash dividend of CNY 5.00 per 10 shares for the year 2025. Announcement • Jul 02
Shandong Wit Dyne Health Co.,Ltd. to Report First Half, 2025 Results on Aug 08, 2025 Shandong Wit Dyne Health Co.,Ltd. announced that they will report first half, 2025 results on Aug 08, 2025 Valuation Update With 7 Day Price Move • Jun 30
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to CN¥35.35, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 21x in the Pharmaceuticals industry in China. Negligible returns to shareholders over past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥39.17 per share. Buy Or Sell Opportunity • Jun 11
Now 25% undervalued Over the last 90 days, the stock has risen 15% to CN¥29.49. The fair value is estimated to be CN¥39.17, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 4.8%. Revenue is forecast to grow by 17% in 2 years. Earnings are forecast to grow by 17% in the next 2 years. New Risk • May 13
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Dividend is not well covered by earnings (120% payout ratio). Board Change • May 08
High number of new directors There are 6 new directors who have joined the board in the last 3 years. Chairman of the Supervisory Board Baojie Shen was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Announcement • Apr 20
Shandong Wit Dyne Health Co.,Ltd., Annual General Meeting, May 13, 2025 Shandong Wit Dyne Health Co.,Ltd., Annual General Meeting, May 13, 2025, at 14:30 China Standard Time. Location: The Company's Meeting Room, Jinan, Shandong China Announcement • Mar 31
Shandong Wit Dyne Health Co.,Ltd. to Report Q1, 2025 Results on Apr 19, 2025 Shandong Wit Dyne Health Co.,Ltd. announced that they will report Q1, 2025 results on Apr 19, 2025 Announcement • Mar 22
Shandong Wit Dyne Health Co.,Ltd. Propose Final Dividend for 2024 Shandong Wit Dyne Health Co.,Ltd. announced on 21 March 2025 the profit distribution proposal for 2024 as follows: Cash dividend/10 shares (tax included): CNY 20.00000000. Valuation Update With 7 Day Price Move • Mar 17
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to CN¥29.43, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 17x in the Pharmaceuticals industry in China. Total loss to shareholders of 4.9% over the past three years. Announcement • Jan 02
Shandong Wit Dyne Health Co.,Ltd. Announces Board Appointments Shandong Wit Dyne Health Co.,Ltd. held its 2nd Extraordinary General Meeting of 2024 on 30 December 2024, approved the appointment of Wu Xinwei as a non-independent director, He Shuwang as a non-independent director. Liu Cheng'an, independent director. Announcement • Dec 31
Shandong Wit Dyne Health Co.,Ltd. to Report Fiscal Year 2024 Results on Mar 21, 2025 Shandong Wit Dyne Health Co.,Ltd. announced that they will report fiscal year 2024 results on Mar 21, 2025 Reported Earnings • Oct 26
Third quarter 2024 earnings released: EPS: CN¥0.14 (vs CN¥0.60 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.14 (down from CN¥0.60 in 3Q 2023). Revenue: CN¥223.6m (down 61% from 3Q 2023). Net income: CN¥33.6m (down 76% from 3Q 2023). Profit margin: 15% (down from 25% in 3Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 12% per year whereas the company’s share price has increased by 9% per year. Valuation Update With 7 Day Price Move • Oct 15
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to CN¥29.72, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 19x in the Pharmaceuticals industry in China. Total returns to shareholders of 11% over the past three years. Announcement • Sep 30
Shandong Wit Dyne Health Co.,Ltd. to Report Q3, 2024 Results on Oct 26, 2024 Shandong Wit Dyne Health Co.,Ltd. announced that they will report Q3, 2024 results on Oct 26, 2024 Valuation Update With 7 Day Price Move • Sep 25
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to CN¥28.75, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 16x in the Pharmaceuticals industry in China. Total returns to shareholders of 13% over the past three years. New Risk • Aug 03
New minor risk - Dividend sustainability The dividend is not well covered by earnings. Payout ratio: 98% Dividend yield: 7.4% This is considered a minor risk. Companies that pay out too much of their earnings are at risk of having to reduce or cut their dividend in future. If earnings growth slows or earnings fall, then there may not be enough earnings to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. However, this risk is mitigated by the fact the dividend is covered by cash flows. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company. Reported Earnings • Jul 10
Second quarter 2024 earnings released: EPS: CN¥0.70 (vs CN¥0.67 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.70 (up from CN¥0.67 in 2Q 2023). Revenue: CN¥582.6m (down 1.5% from 2Q 2023). Net income: CN¥163.2m (up 3.2% from 2Q 2023). Profit margin: 28% (up from 27% in 2Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Announcement • Jun 29
Shandong Wit Dyne Health Co.,Ltd. to Report First Half, 2024 Results on Aug 01, 2024 Shandong Wit Dyne Health Co.,Ltd. announced that they will report first half, 2024 results on Aug 01, 2024 Declared Dividend • May 11
Dividend increased to CN¥2.00 Dividend of CN¥2.00 is 150% higher than last year. Ex-date: 16th May 2024 Payment date: 16th May 2024 Dividend yield will be 5.5%, which is higher than the industry average of 1.9%. Sustainability & Growth Dividend is covered by both earnings (79% earnings payout ratio) and cash flows (46% cash payout ratio). The dividend has increased by an average of 39% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 46% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Announcement • May 11
Shandong Wit Dyne Health Co.,Ltd. Announces Final Cash Dividend on A Shares for the Year 2023, Payable on 16 May 2024 Shandong Wit Dyne Health Co.,Ltd. announced 2023 final profit distribution plan to be implemented (A shares): Cash dividend of CNY 20.00000000 per ten 10 shares (tax included). Record date: 15 May 2024. Ex-date: 16 May 2024. Payment date: 16 May 2024. Reported Earnings • Apr 18
First quarter 2024 earnings released: EPS: CN¥0.72 (vs CN¥0.70 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.72 (up from CN¥0.70 in 1Q 2023). Revenue: CN¥571.8m (up 1.8% from 1Q 2023). Net income: CN¥168.6m (up 3.0% from 1Q 2023). Profit margin: 30% (in line with 1Q 2023). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. Announcement • Mar 30
Shandong Wit Dyne Health Co.,Ltd. to Report Q1, 2024 Results on Apr 18, 2024 Shandong Wit Dyne Health Co.,Ltd. announced that they will report Q1, 2024 results on Apr 18, 2024 Announcement • Mar 16
Shandong Wit Dyne Health Co.,Ltd., Annual General Meeting, Apr 16, 2024 Shandong Wit Dyne Health Co.,Ltd., Annual General Meeting, Apr 16, 2024, at 14:30 China Standard Time. Reported Earnings • Mar 16
Full year 2023 earnings: EPS and revenues exceed analyst expectations Full year 2023 results: EPS: CN¥2.50 (up from CN¥2.25 in FY 2022). Revenue: CN¥2.48b (up 6.1% from FY 2022). Net income: CN¥585.3m (up 11% from FY 2022). Profit margin: 24% (up from 23% in FY 2022). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 9.0%. Earnings per share (EPS) also surpassed analyst estimates by 3.7%. Revenue is forecast to grow 8.4% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 20% per year whereas the company’s share price has increased by 16% per year. Reported Earnings • Jan 20
Full year 2023 earnings released: EPS: CN¥2.49 (vs CN¥2.25 in FY 2022) Full year 2023 results: EPS: CN¥2.49 (up from CN¥2.25 in FY 2022). Revenue: CN¥2.47b (up 5.7% from FY 2022). Net income: CN¥583.9m (up 11% from FY 2022). Profit margin: 24% (up from 23% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.6% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. Announcement • Dec 30
Shandong Wit Dyne Health Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 16, 2024 Shandong Wit Dyne Health Co.,Ltd. announced that they will report fiscal year 2023 results on Mar 16, 2024 Reported Earnings • Oct 20
Third quarter 2023 earnings released: EPS: CN¥0.60 (vs CN¥0.67 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.60 (down from CN¥0.67 in 3Q 2022). Revenue: CN¥565.5m (down 4.7% from 3Q 2022). Net income: CN¥139.0m (down 12% from 3Q 2022). Profit margin: 25% (down from 27% in 3Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 19
Second quarter 2023 earnings released: EPS: CN¥0.67 (vs CN¥0.63 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.67 (up from CN¥0.63 in 2Q 2022). Revenue: CN¥591.8m (down 4.5% from 2Q 2022). Net income: CN¥158.1m (up 6.4% from 2Q 2022). Profit margin: 27% (up from 24% in 2Q 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Reported Earnings • Jul 12
Second quarter 2023 earnings released: EPS: CN¥0.67 (vs CN¥0.63 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.67. Revenue: CN¥591.8m (down 4.5% from 2Q 2022). Net income: CN¥138.9m (down 6.5% from 2Q 2022). Profit margin: 24% (in line with 2Q 2022). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Announcement • Jul 01
Shandong Shanda Wit Science and Technology Co., Ltd. to Report First Half, 2023 Results on Aug 19, 2023 Shandong Shanda Wit Science and Technology Co., Ltd. announced that they will report first half, 2023 results on Aug 19, 2023 Reported Earnings • Mar 11
Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2022 results: EPS: CN¥2.25 (up from CN¥1.62 in FY 2021). Revenue: CN¥2.34b (up 16% from FY 2021). Net income: CN¥526.9m (up 39% from FY 2021). Profit margin: 23% (up from 19% in FY 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 1.2%. Earnings per share (EPS) missed analyst estimates by 7.8%. Revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth. Reported Earnings • Jan 23
Full year 2022 earnings released: EPS: CN¥2.21 (vs CN¥1.62 in FY 2021) Full year 2022 results: EPS: CN¥2.21 (up from CN¥1.62 in FY 2021). Revenue: CN¥2.34b (up 16% from FY 2021). Net income: CN¥514.0m (up 35% from FY 2021). Profit margin: 22% (up from 19% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth. Board Change • Nov 16
Less than half of directors are independent There are 8 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 8 new directors. 2 experienced directors. 2 highly experienced directors. 3 independent directors (5 non-independent directors). Chairman Xiaoping Zhu is the most experienced director on the board, commencing their role in 2008. Independent Director Zhiyuan Zhang was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Reported Earnings • Oct 21
Third quarter 2022 earnings released: EPS: CN¥0.67 (vs CN¥0.38 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.67 (up from CN¥0.38 in 3Q 2021). Revenue: CN¥593.5m (up 5.8% from 3Q 2021). Net income: CN¥157.8m (up 76% from 3Q 2021). Profit margin: 27% (up from 16% in 3Q 2021). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 27% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Oct 18
Investor sentiment improved over the past week After last week's 19% share price gain to CN¥48.97, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 20x in the Pharmaceuticals industry in China. Total returns to shareholders of 128% over the past three years. Reported Earnings • Jul 07
Second quarter 2022 earnings released: EPS: CN¥0.63 (vs CN¥0.51 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.63 (up from CN¥0.51 in 2Q 2021). Revenue: CN¥619.7m (up 19% from 2Q 2021). Net income: CN¥148.6m (up 24% from 2Q 2021). Profit margin: 24% (in line with 2Q 2021). Over the next year, revenue is forecast to grow 12%, compared to a 24% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has only increased by 24% per year, which means it is significantly lagging earnings growth. Board Change • Apr 27
Less than half of directors are independent There are 6 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Director Yuqin Lv was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Announcement • Apr 15
Shandong Shanda Wit Science and Technology Co., Ltd. Approves Cash Dividend for 2021 Shandong Shanda Wit Science and Technology Co., Ltd. approved the cash dividend distribution proposal of CNY 8.00000000 per 10 shares (tax included) for 2021 in Annual General Meeting of 2021 held on 13 April 2022. Reported Earnings • Mar 11
Full year 2021 earnings: EPS and revenues miss analyst expectations Full year 2021 results: EPS: CN¥1.62 (up from CN¥1.24 in FY 2020). Revenue: CN¥2.03b (up 11% from FY 2020). Net income: CN¥380.3m (up 31% from FY 2020). Profit margin: 19% (up from 16% in FY 2020). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 2.4%. Earnings per share (EPS) also missed analyst estimates by 7.4%. Over the next year, revenue is forecast to grow 12%, compared to a 25% growth forecast for the pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has only increased by 20% per year, which means it is significantly lagging earnings growth. Reported Earnings • Jan 23
Full year 2021 earnings: EPS and revenues miss analyst expectations Full year 2021 results: EPS: CN¥1.63 (up from CN¥1.24 in FY 2020). Revenue: CN¥2.03b (up 12% from FY 2020). Net income: CN¥353.9m (up 22% from FY 2020). Profit margin: 17% (up from 16% in FY 2020). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 2.1%. Earnings per share (EPS) also missed analyst estimates by 6.9%. Over the next year, revenue is forecast to grow 10.0%, compared to a 24% growth forecast for the pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has only increased by 30% per year, which means it is significantly lagging earnings growth. Reported Earnings • Oct 23
Third quarter 2021 earnings released: EPS CN¥0.38 (vs CN¥0.39 in 3Q 2020) The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: CN¥561.1m (up 5.1% from 3Q 2020). Net income: CN¥89.5m (down 3.3% from 3Q 2020). Profit margin: 16% (down from 17% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has only increased by 29% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Sep 14
Investor sentiment deteriorated over the past week After last week's 16% share price decline to CN¥27.98, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 23x in the Pharmaceuticals industry in China. Total returns to shareholders of 94% over the past three years. Valuation Update With 7 Day Price Move • Aug 05
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥34.72, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 22x in the Pharmaceuticals industry in China. Total returns to shareholders of 120% over the past three years. Reported Earnings • Jul 31
Second quarter 2021 earnings released: EPS CN¥0.51 (vs CN¥0.37 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥522.0m (up 2.7% from 2Q 2020). Net income: CN¥120.3m (up 41% from 2Q 2020). Profit margin: 23% (up from 17% in 2Q 2020). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has only increased by 23% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Jul 05
Investor sentiment improved over the past week After last week's 15% share price gain to CN¥30.00, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 26x in the Pharmaceuticals industry in China. Total returns to shareholders of 72% over the past three years. Announcement • May 26
Shandong Shanda Wit Science and Technology Co., Ltd. Announces 2020 Final Distribution Plan, Payable on 01 June 2021 Shandong Shanda Wit Science and Technology Co., Ltd. announced 2020 final distribution plan to be implemented (A shares). The company announced Cash dividend per 10 shares (tax included) is CNY 3.50000000. Record date is 31 May 2021. Ex-date is 01 June 2021. Payment date is 01 June 2021. Reported Earnings • Apr 25
First quarter 2021 earnings released: EPS CN¥0.47 (vs CN¥0.21 in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥489.3m (up 51% from 1Q 2020). Net income: CN¥109.0m (up 120% from 1Q 2020). Profit margin: 22% (up from 15% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Apr 09
Investor sentiment improved over the past week After last week's 22% share price gain to CN¥28.14, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 26x in the Pharmaceuticals industry in China. Total returns to shareholders of 22% over the past three years. Reported Earnings • Mar 27
Full year 2020 earnings released: EPS CN¥1.25 (vs CN¥0.87 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥1.82b (up 1.1% from FY 2019). Net income: CN¥292.3m (up 43% from FY 2019). Profit margin: 16% (up from 11% in FY 2019). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Announcement • Feb 24
Shandong Shanda Wit Science and Technology Co., Ltd. to Report Fiscal Year 2020 Results on Mar 27, 2021 Shandong Shanda Wit Science and Technology Co., Ltd. announced that they will report fiscal year 2020 results on Mar 27, 2021 Is New 90 Day High Low • Jan 26
New 90-day low: CN¥22.35 The company is down 21% from its price of CN¥28.22 on 28 October 2020. The Chinese market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 3.0% over the same period. Reported Earnings • Jan 20
Full year 2020 earnings released: EPS CN¥1.25 The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥1.82b (up 1.1% from FY 2019). Net income: CN¥292.3m (up 43% from FY 2019). Profit margin: 16% (up from 11% in FY 2019). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Is New 90 Day High Low • Dec 23
New 90-day low: CN¥24.00 The company is down 10.0% from its price of CN¥26.79 on 24 September 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 1.0% over the same period. Is New 90 Day High Low • Dec 02
New 90-day low: CN¥25.78 The company is down 13% from its price of CN¥29.59 on 03 September 2020. The Chinese market is down 1.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 14% over the same period. Reported Earnings • Oct 25
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥277.1m, up 96% from the prior year. Total revenue was CN¥1.85b over the last 12 months, up 18% from the prior year. Announcement • Oct 17
Shandong Shanda Wit Science and Technology Co., Ltd. to Report Q3, 2020 Results on Oct 24, 2020 Shandong Shanda Wit Science and Technology Co., Ltd. announced that they will report Q3, 2020 results on Oct 24, 2020 Announcement • Jul 18
Shandong Shanda Wit Science and Technology Co., Ltd. to Report First Half, 2020 Results on Aug 08, 2020 Shandong Shanda Wit Science and Technology Co., Ltd. announced that they will report first half, 2020 results on Aug 08, 2020